Abstract

Objective: Actinium-225, and its daughter Bismuth-213, have great promise in Alpha Immuno Therapy (AIT) for treatment of various disease modalities. Unfortunately, current production levels of actinium-225 do not support broad use of either actinium-225 or bismuth-213 in development or use for disease treatment. Further, the current cost per millicurie is much too high to be sustainable long term. Resolution of both supply and cost issues allows clinical research to proceed through clinical trials and potentially produce one or more effective therapies for cancer or infectious diseases that could benefit the public.

Methods: NorthStar Medical Technologies, LLC, has investigated several routes that could lead to commercial scale production of actinium-225.

Results: This article will discuss those efforts and results to date.

Conclusion: The outlook for future supplies of actinium-225 from multiple sources to support clinical needs is encouraging.

Keywords: 225Ac, actinium-225, 213Bi, bismuth-213, alpha immuno therapy AIT, targeted alpha therapy TAT.

Graphical Abstract